AN2 Therapeutics, Inc.

NasdaqGS:ANTX Stock Report

Market Cap: US$37.3m

AN2 Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ANTX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
03 Jan 25SellUS$12,958Joshua EizenIndividual9,663US$1.34
03 Jan 25SellUS$2,721Stephen PriorIndividual2,029US$1.34
03 Jan 25SellUS$3,965Sanjay ChandaIndividual2,957US$1.34
03 Jan 25SellUS$3,965Lucy DayIndividual2,957US$1.34
10 Dec 24BuyUS$86,708Mountain Group Capital, LLCCompany60,000US$1.49
27 Nov 24BuyUS$2,800Joseph ZakrzewskiIndividual2,000US$1.40
27 Nov 24BuyUS$105,685Mountain Group Capital, LLCCompany75,000US$1.42
20 Nov 24BuyUS$213,128Robin ReadnourIndividual200,000US$1.16
19 Nov 24BuyUS$25,046Joseph ZakrzewskiIndividual25,000US$1.01
18 Nov 24BuyUS$49,970Eric EasomIndividual50,000US$1.00
14 Aug 24BuyUS$1,560,000BML Capital Management, LLCCompany1,500,000US$1.04
09 Aug 24SellUS$3,807,102RA Capital Management, L.P.Company3,525,094US$1.08

Insider Trading Volume

Insider Buying: ANTX insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ANTX?
Owner TypeNumber of SharesOwnership Percentage
Public Companies1,362,4994.56%
Individual Insiders1,929,3276.46%
Institutions5,484,96518.4%
Hedge Funds5,749,43219.2%
VC/PE Firms5,928,61519.8%
General Public9,424,05231.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 67.54% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19.2%
BML Capital Management, LLC
5,749,432US$7.2m0%3.98%
7.94%
Adjuvant Capital, LP
2,373,500US$3.0m0%no data
6.69%
RA Capital Management, L.P.
1,999,997US$2.5m-64%0.03%
5.2%
TCG Crossover Management, LLC
1,555,118US$1.9m0%0.2%
4.56%
Pfizer Inc.
1,362,499US$1.7m0%no data
4.22%
Eric Easom
1,262,012US$1.6m4.13%no data
4.13%
Mountain Group Capital, LLC
1,234,861US$1.5m37.2%100.0%
3.49%
The Vanguard Group, Inc.
1,041,527US$1.3m0%no data
1.81%
Joseph Zakrzewski
540,895US$676.1k7.3%no data
1.49%
Acuitas Investments, LLC
445,783US$557.2k0%0.16%
1.42%
Renaissance Technologies LLC
423,800US$529.7k2,860%no data
1.33%
Millennium Management LLC
397,925US$497.4k-24.4%no data
1.05%
Adage Capital Management, L.P.
312,615US$390.8k0%no data
1.01%
BlackRock, Inc.
301,176US$376.5k0.49%no data
0.74%
Geode Capital Management, LLC
220,162US$275.2k21.7%no data
0.66%
Bridgeway Capital Management, LLC
197,000US$246.3k88.9%no data
0.6%
Two Sigma Investments, LP
177,840US$222.3k34.6%no data
0.4%
Two Sigma Advisers, LP
120,900US$151.1k-10.2%no data
0.34%
Aldebaran Capital, LLC
100,500US$125.6k0%0.12%
0.28%
Marquette Asset Management, LLC
83,206US$104.0k29%0.02%
0.27%
Jacobs Levy Equity Management Inc
79,359US$99.2k0%no data
0.22%
Schonfeld Strategic Advisors LLC
66,100US$82.6k204%no data
0.2%
State Street Global Advisors, Inc.
60,302US$75.4k0%no data
0.14%
Acadian Asset Management LLC
42,335US$52.9k-51.3%no data
0.11%
Northern Trust Global Investments
32,595US$40.7k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/24 23:30
End of Day Share Price 2025/01/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AN2 Therapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Liisa BaykoEvercore ISI
Douglas BuchananJMP Securities
Joseph SchwartzLeerink Partners LLC